{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:30:50Z","timestamp":1791873050248,"version":"4.3.4"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T00:00:00Z","timestamp":1662336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T00:00:00Z","timestamp":1662336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s40272-022-00532-z","type":"journal-article","created":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T01:02:32Z","timestamp":1662339752000},"page":"715-720","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Phentermine\/Topiramate: Pediatric First Approval"],"prefix":"10.1007","volume":"24","author":[{"given":"Sohita","family":"Dhillon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,5]]},"reference":[{"key":"532_CR1","unstructured":"Centers for Disease Control and Prevention. Childhood obesity facts. 2022. https:\/\/www.cdc.gov\/obesity\/data\/childhood.html. Accessed 24 July 2022."},{"issue":"3","key":"532_CR2","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1210\/jc.2016-2573","volume":"102","author":"DM Styne","year":"2017","unstructured":"Styne DM, Arslanian SA, Connor EL, et al. Pediatric obesity-assessment, treatment, and prevention: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2017;102(3):709\u201357.","journal-title":"J Clin Endocrinol Metab"},{"key":"532_CR3","unstructured":"VIVUS LLC. QSYMIA (phentermine and topiramate extended-release capsules): US prescribing information. 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/022580s021lbl.pdf. Accessed 18 July 2022."},{"key":"532_CR4","unstructured":"VIVUS LLC. FDA approves QSYMIA\u00ae for the treatment of obesity in adolescents ages 12\u201317 [media release]. 20 July 2022. https:\/\/ir.vivus.com\/news-releases\/news-release-details\/fda-approves-qsymiar-treatment-obesity-adolescents-ages-12-17."},{"key":"532_CR5","unstructured":"Catalent Pharma Solutions. Catalent enters into commercial supply agreement with VIVUS for Qsymia\u2122 once-daily combination-extended-release capsules [media release]. 2 Oct 2012. https:\/\/www.catalent.com."},{"key":"532_CR6","unstructured":"Vivus. VIVUS announces acquisition of topiramate-related patents from Janssen Pharmaceuticals [media release]. 25 Aug 2014. https:\/\/ir.vivus.com\/news-releases\/news-release-details\/vivus-announces-acquisition-topiramate-related-patents-janssen."},{"key":"532_CR7","unstructured":"Vivus. VIVUS and Alvogen announce marketing agreement for Qsymia\u00ae in the Republic of Korea [media release]. 5 Sep 2017. https:\/\/ir.vivus.com\/news-releases\/news-release-details\/vivus-and-alvogen-announce-marketing-agreement-qsymiar-republic."},{"issue":"4","key":"532_CR8","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1111\/dom.13910","volume":"22","author":"DS Hsia","year":"2020","unstructured":"Hsia DS, Gosselin NH, Williams J, et al. A randomized, double-blind, placebo-controlled, pharmacokinetic and pharmacodynamic study of a fixed-dose combination of phentermine\/topiramate in adolescents with obesity. Diabetes Obes Metab. 2020;22(4):480\u201391.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"532_CR9","first-page":"EVIDoa2200014","volume":"1","author":"S Kelly Aaron","year":"2022","unstructured":"Kelly Aaron S, Bensignor Megan O, Hsia Daniel S, et al. Phentermine\/topiramate for the treatment of adolescent obesity. NEJM Evid. 2022;1(6):EVIDoa2200014.","journal-title":"NEJM Evid."}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-022-00532-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-022-00532-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-022-00532-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T02:14:00Z","timestamp":1666664040000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-022-00532-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,5]]},"references-count":9,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["532"],"URL":"https:\/\/doi.org\/10.1007\/s40272-022-00532-z","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,5]]},"assertion":[{"value":"5 September 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Sohita Dhillon is a contracted employee of Adis International Ltd\/Springer Nature and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}